Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2016, Article ID 7594306, 9 pages
http://dx.doi.org/10.1155/2016/7594306
Review Article

Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices

1School of Medicine, Department of Gynecology and Obstetrics, Division of Maternal Fetal Medicine and Reproductive Infectious Diseases, Emory University, 550 Peachtree Street, Atlanta, GA 30308, USA
2School of Medicine, Department of Gynecology and Obstetrics, Division of Family Planning, Emory University, 550 Peachtree Street, Atlanta, GA 30308, USA
3School of Medicine, Department of Gynecology and Obstetrics, Division of Maternal Fetal Medicine, Emory University, 550 Peachtree Street, Atlanta, GA 30308, USA
4School of Medicine, Department of Pediatrics, Division of Infectious Diseases, Emory University, 2015 Uppergate Drive, NE, Atlanta, GA 30322, USA

Received 23 February 2016; Revised 8 June 2016; Accepted 16 June 2016

Academic Editor: Bryan Larsen

Copyright © 2016 Bassam H. Rimawi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Center for Disease Control and Prevention (CDC), HIV among Pregnant Women, Infants, and Children in the United States, CDC, Atlanta, Ga, USA, 2012.
  2. A. P. Kourtis, F. K. Lee, E. J. Abrams, D. J. Jamieson, and M. Bulterys, “Mother-to-child transmission of HIV-1: timing and implications for prevention,” The Lancet Infectious Diseases, vol. 6, no. 11, pp. 726–732, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. A. Ioannidis, E. J. Abrams, A. Ammann et al., “Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL,” Journal of Infectious Diseases, vol. 183, no. 4, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Mandelbrot, J. Le Chenadec, A. Berrebi et al., “Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French perinatal cohort,” The Journal of the American Medical Association, vol. 280, no. 1, pp. 55–60, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. “The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group,” The New England Journal of Medicine, vol. 340, no. 13, pp. 977–987, 1999.
  6. J. Jean, A. Coll, M. Monda, J. Potter, and D. Jones, “Perspectives on safer conception practices and preconception counseling among women living with HIV,” Health Care for Women International, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. A. F. Camacho-Gonzalez, M.-H. Kingbo, A. Boylan, A. R. Eckard, A. Chahroudi, and R. Chakraborty, “Missed opportunities for prevention of mother-to-child transmission in the United States,” AIDS, vol. 29, no. 12, pp. 1511–1515, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Nesheim, L. F. Harris, and M. Lampe, “Elimination of perinatal HIV infection in the USA and other high-income countries: achievements and challenges,” Current Opinion in HIV & AIDS, vol. 8, no. 5, pp. 447–456, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Nesheim, A. Taylor, M. A. Lampe et al., “A framework for elimination of perinatal transmission of HIV in the United States,” Pediatrics, vol. 130, no. 4, pp. 738–744, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. S. Coll, J. E. Potter, N. Chakhtoura, M. L. Alcaide, R. Cook, and D. L. Jones, “Providers' perspectives on preconception counseling and safer conception for HIV-infected women,” AIDS Care, vol. 28, no. 4, pp. 513–518, 2016. View at Publisher · View at Google Scholar
  11. S. Chaithongwongwatthana, “Conceptive options for people living with HIV,” Journal of the Medical Association of Thailand, vol. 98, supplement 1, pp. S123–S126, 2015. View at Google Scholar · View at Scopus
  12. M. V. Sauer, “Sperm washing techniques address the fertility needs of HIV-seropositive men: a clinical review,” Reproductive BioMedicine Online, vol. 10, no. 1, pp. 135–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. G. C. Jayaraman, J. K. Preiksaitis, and B. Larke, “Mandatory reporting of HIV infection and opt-out prenatal screening for HIV infection: effect on testing rates,” Canadian Medical Association Journal, vol. 168, no. 6, pp. 679–682, 2003. View at Google Scholar · View at Scopus
  14. “Committee opinion no: 635: prenatal and perinatal human immunodeficiency virus testing: expanded recommendations,” Obstetrics & Gynecology, vol. 125, no. 6, pp. 1544–1547, 2015. View at Publisher · View at Google Scholar
  15. M. Bulterys, D. J. Jamieson, M. J. O'Sullivan et al., “Rapid HIV-1 testing during labor: a multicenter study,” The Journal of the American Medical Association, vol. 292, no. 2, pp. 219–223, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. ACOG Committee on Obstetric Practice, “ACOG committee opinion number 304, November 2004. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations,” Obstetrics & Gynecology, vol. 104, no. 5, part 1, pp. 1119–1124, 2004. View at Google Scholar
  17. B. Weber, R. Thorstensson, S. Tanprasert, U. Schmitt, and W. Melchior, “Reduction of the diagnostic window in three cases of human immunodeficiency-1 subtype E primary infection with fourth-generation HIV screening assays,” Vox Sanguinis, vol. 85, no. 2, pp. 73–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. P. L. Havens, R. Chakraborty, E. Cooper et al., “HIV testing and prophylaxis to prevent mother-to-child transmission in the united states,” Pediatrics, vol. 122, no. 5, pp. 1127–1134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. N. M. Doyle, J. E. Levison, and M. O. Gardner, “Rapid HIV versus enzyme-linked immunosorbent assay screening in a low-risk Mexican American population presenting in labor: a cost-effectiveness analysis,” American Journal of Obstetrics and Gynecology, vol. 193, no. 3, part 2, pp. 1280–1285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. Centers for Disease Control and Prevention, “Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults,” The Journal of the American Medical Association, vol. 269, no. 6, pp. 729–730, 1993. View at Publisher · View at Google Scholar
  21. M. W. F. Rac and J. S. Sheffield, “Prevention and management of viral hepatitis in pregnancy,” Obstetrics and Gynecology Clinics of North America, vol. 41, no. 4, pp. 573–592, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. R. S. Brown Jr., B. J. McMahon, A. S. F. Lok et al., “Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis,” Hepatology, vol. 63, no. 1, pp. 319–333, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Dionne-Odom, A. T. N. Tita, and N. S. Silverman, “Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission,” American Journal of Obstetrics and Gynecology, vol. 214, no. 1, pp. 6–14, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. Advisory Committee on Immunization Practices Centers for Disease Control and Prevention, “Guiding principles for development of ACIP recommendations for vaccination during pregnancy and breastfeeding,” Morbidity and Mortality Weekly Report, vol. 57, no. 21, p. 580, 2008. View at Google Scholar
  25. A. D. White and E. B. Andrews, “The pregnancy registry program at glaxo wellcome company,” Journal of Allergy and Clinical Immunology, vol. 103, no. 2, pp. S362–S363, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Y. Chen, H. J. Ribaudo, S. Souda et al., “Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana,” The Journal of Infectious Diseases, vol. 206, no. 11, pp. 1695–1705, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Yu, W.-Y. Li, R. Y. Chen et al., “Pregnancy outcomes and risk factors for low birth weight and preterm delivery among HIV-infected pregnant women in Guangxi, China,” Chinese Medical Journal, vol. 125, no. 3, pp. 403–409, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Martin and G. P. Taylor, “Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study,” Journal of Infectious Diseases, vol. 196, no. 4, pp. 558–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Lopez, F. Figueras, S. Hernandez et al., “Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART,” AIDS, vol. 26, no. 1, pp. 37–43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Aaron, A. Bonacquisti, L. Mathew, G. Alleyne, L. P. Bamford, and J. F. Culhane, “Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy,” Infectious Diseases in Obstetrics and Gynecology, vol. 2012, Article ID 135030, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Sibiude, J. Warszawski, R. Tubiana et al., “Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?” Clinical Infectious Diseases, vol. 54, no. 9, pp. 1348–1360, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Minkoff and M. Augenbraun, “Antiretroviral therapy for pregnant women,” American Journal of Obstetrics and Gynecology, vol. 176, no. 2, pp. 478–489, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. A. B. Morris, A. R. Dobles, S. Cu-Uvin et al., “Protease inhibitor use in 233 pregnancies,” Journal of Acquired Immune Deficiency Syndromes, vol. 40, no. 1, pp. 30–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. A. M. Cotter, A. G. Garcia, M. L. Duthely, B. Luke, and M. J. O'Sullivan, “Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?” Journal of Infectious Diseases, vol. 193, no. 9, pp. 1195–1201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Sibiude, L. Mandelbrot, S. Blanche et al., “Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11),” PLoS Medicine, vol. 11, no. 4, Article ID e1001635, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. C. Marazzi, L. Palombi, K. Nielsen-Saines et al., “Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes,” AIDS, vol. 25, no. 13, pp. 1611–1618, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Li, M. M. Sando, D. Spiegelman et al., “Antiretroviral therapy in relation to birth outcomes among HIV-infected Women: a cohort study,” Journal of Infectious Diseases, vol. 213, no. 7, pp. 1057–1064, 2016. View at Publisher · View at Google Scholar
  38. L. Mofenson, “Antiretroviral therapy and adverse pregnancy outcome: the elephant in the room?” Journal of Infectious Diseases, vol. 213, no. 7, pp. 1051–1054, 2016. View at Publisher · View at Google Scholar
  39. K. M. Powis and R. L. Shapiro, “Protease inhibitors and adverse birth outcomes: is progesterone the missing piece to the puzzle?” The Journal of Infectious Diseases, vol. 211, no. 1, pp. 4–7, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Fiore, M.-L. Newell, D. Trabattoni et al., “Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women,” Journal of Reproductive Immunology, vol. 70, no. 1-2, pp. 143–150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Fauchet, J.-M. Treluyer, E. Valade et al., “Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?” British Journal of Clinical Pharmacology, vol. 78, no. 6, pp. 1387–1396, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. M. K. Buchberg, F. E. Fletcher, D. J. Vidrine et al., “A mixed-methods approach to understanding barriers to postpartum retention in care among low-income, HIV-infected women,” AIDS Patient Care and STDs, vol. 29, no. 3, pp. 126–132, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. L. H. Rubin, J. A. Cook, D. D. Grey et al., “Perinatal depressive symptoms in HIV-infected versus HIV-uninfected women: a prospective study from preconception to postpartum,” Journal of Women's Health, vol. 20, no. 9, pp. 1287–1295, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. J. R. Ickovics, M. E. Hamburger, D. Vlahov et al., “Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study,” The Journal of the American Medical Association, vol. 285, no. 11, pp. 1466–1474, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Neubert, M. Pfeffer, A. Borkhardt et al., “Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral Zidovudine,” BMC Pregnancy and Childbirth, vol. 13, article 22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. W. Ferguson, M. Goode, A. Walsh, P. Gavin, and K. Butler, “Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting,” Pediatric Infectious Disease Journal, vol. 30, no. 5, pp. 408–412, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Nielsen-Saines, D. H. Watts, V. G. Veloso et al., “Three postpartum antiretroviral regimens to prevent intrapartum HIV infection,” The New England Journal of Medicine, vol. 366, no. 25, pp. 2368–2379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. W. E. Ivy III, K. L. Dominguez, N. Y. Rakhmanina et al., “Premastication as a route of pediatric HIV transmission: case-control and cross-sectional investigations,” Journal of Acquired Immune Deficiency Syndromes, vol. 59, no. 2, pp. 207–212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. D. M. Ashton, “Elective delivery at less than 39 weeks,” Current Opinion in Obstetrics and Gynecology, vol. 22, no. 6, pp. 506–510, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. Committee on Obstetric Practice, “ACOG committee opinion-scheduled cesarean delivery and the prevention of vertical transmission of HIV infection,” International Journal of Gynecology & Obstetrics, vol. 73, no. 3, pp. 279–281, 2001. View at Publisher · View at Google Scholar
  51. A. R. Fleischman, M. Oinuma, and S. L. Clark, “Rethinking the definition of ‘term pregnancy’,” Obstetrics and Gynecology, vol. 116, no. 1, pp. 136–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. “Erythropoietin for zidovudine-induced anemia,” The New England Journal of Medicine, vol. 323, no. 15, pp. 1069–1070, 1990. View at Publisher · View at Google Scholar
  53. T. J. Nagu, M. Kanyangarara, C. Hawkins et al., “Elevated alanine aminotransferase in antiretroviral-naïve HIV-infected African patients: magnitude and risk factors,” HIV Medicine, vol. 13, no. 9, pp. 541–548, 2012. View at Publisher · View at Google Scholar
  54. N. M. E. Oliveira, F. A. U. Y. Ferreira, R. Y. U. Yonamine, and E. Z. I. Chehter, “Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review,” Einstein, vol. 12, no. 1, pp. 112–119, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. R. C. Wimalasundera, N. Larbalestier, J. H. Smith et al., “Pre-eclampsia, antiretroviral therapy, and immune reconstitution,” The Lancet, vol. 360, no. 9340, pp. 1152–1154, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Mirochnick and E. Capparelli, “Pharmacokinetics of antiretrovirals in pregnant women,” Clinical Pharmacokinetics, vol. 43, no. 15, pp. 1071–1087, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. E. De Clercq, “Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF),” Biochemical Pharmacology, 2016. View at Publisher · View at Google Scholar
  58. G. K. Siberry, D. L. Jacobson, H. J. Kalkwarf et al., “Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy,” Clinical Infectious Diseases, vol. 61, no. 6, pp. 996–1003, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. R. A. Murphy, H. Sunpath, D. R. Kuritzkes, F. Venter, and R. T. Gandhi, “Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary,” Journal of Infectious Diseases, vol. 196, supplement 3, pp. S449–S456, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Bussmann, C. W. Wester, C. N. Wester et al., “Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana,” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 3, pp. 269–273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Ford, L. Mofenson, Z. Shubber et al., “Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis,” AIDS, vol. 28, supplement 2, pp. S123–S131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. P. L. Williams, M. J. Crain, C. Yildirim et al., “Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants,” JAMA Pediatrics, vol. 169, no. 1, pp. 48–55, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. M. S. Baylor and R. Johann-Liang, “Hepatotoxicity associated with nevirapine use,” Journal of Acquired Immune Deficiency Syndromes, vol. 35, no. 5, pp. 538–539, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Manfredi and L. Calza, “Safety issues about nevirapine administration in HIV-infected pregnant women,” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 3, pp. 365–368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. Antiretroviral Pregnancy Registry Steering Committee, Antiretroviral Pregnancy Registry International Interim Report for 1989–2014, Registry Coordinating Center, Wilmington, NC, USA, 2014, http://www.APRegistry.com/.
  66. K. Morris, “Short course of AZT halves HIV-1 perinatal transmission,” The Lancet, vol. 351, no. 9103, p. 651, 1998. View at Google Scholar · View at Scopus